Sandoz Group AG | Finanzwire

BRIEF

published on 03/10/2026 at 07:05, 1 month 12 days ago

Sandoz Establishes New Biosimilar Unit, Appoints Armin Metzger

Biosimilars Strategic Growth Leadership Generics Sandoz
PRESS RELEASE

published on 03/10/2026 at 07:00, 1 month 12 days ago

Sandoz creates new global biosimilar development, manufacturing and supply unit, appoints industry veteran Armin Metzger to lead next phase of growth
Sandoz creates new global biosimilar development, manufacturing, and supply unit with appointment of industry veteran Armin Metzger to lead growth strategy

Manufacturing Development Biosimilar Sandoz Armin Metzger
BRIEF

published on 02/25/2026 at 07:05, 1 month 25 days ago

Sandoz Reports Strong Financial Results and Forecasted Growth for 2026

Financial Results Operational Efficiencies 2026 Forecast Biosimilars Growth Generics Challenges
PRESS RELEASE

published on 02/25/2026 at 07:00, 1 month 25 days ago

Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth
Sandoz reports strong full-year results for 2025 with net sales growth and core EBITDA margin expansion. The guidance for 2026 anticipates further growth in net sales and core EBITDA margin

Net Sales Growth Full-year Results Sandoz Financial Guidance 2026 Core EBITDA Margin Expansion
BRIEF

published on 02/23/2026 at 11:05, 1 month 27 days ago

Sandoz Gains EU Approval for Ranluspec, Enhancing Biosimilars Position

European Commission Biosimilars Ophthalmology Sandoz Strategy Ranluspec Approval
PRESS RELEASE

published on 02/23/2026 at 11:00, 1 month 27 days ago

Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology
Sandoz confirms European Commission approval for Ranluspec®, strengthening biosimilars leadership in ophthalmology. Launch planned for second half of 2026

Biosimilars Ophthalmology Sandoz European Commission Approval Ranluspec
BRIEF

published on 02/18/2026 at 07:05, 2 months 4 days ago

Sandoz Expands Enzeevu® Label with FDA Approval for Retinal Indications

FDA Approval Biosimilars Sandoz Enzeevu Retinal Indications
PRESS RELEASE

published on 02/18/2026 at 07:00, 2 months 4 days ago

Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications
Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label to include multiple retinal indications, offering new treatment options for retinal diseases

FDA Approval Vision Care Sandoz Enzeevu Retinal Indications
BRIEF

published on 01/14/2026 at 12:05, 3 months 8 days ago

Sandoz Secures EU Approval for Ondibta® in Diabetes Treatment

European Commission Biosimilars Diabetes Treatment Ondibta® Approval Sandoz Strategy
PRESS RELEASE

published on 01/14/2026 at 12:00, 3 months 8 days ago

Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes
Sandoz confirms European Commission approval of Ondibta® (insulin glargine), strengthening overall biosimilars leadership and position in diabetes. Expected launch by early 2027

Diabetes European Commission Biosimilars Sandoz Ondibta

Published on 04/22/2026 at 13:30, 6 minutes ago

ZTEST Electronics Inc. Announces Its Intention to Effect a Normal Course Issuer Bid
Published on 04/22/2026 at 13:00, 36 minutes ago

AmeriTrust Announces 2025 Annual Financial Results
Published on 04/22/2026 at 13:00, 36 minutes ago

Kalo Gold Defines Kilometre-Scale Epithermal Gold Targets and Structural Corridors at Wainikoro Within a 40 km Gold Corridor, Vatu Aurum, Fiji
Published on 04/22/2026 at 13:00, 36 minutes ago

Revolve Accelerates Growth of Distributed Generation Portfolio with Definitive Agreements for 9 New Solar Projects in Mexico
Published on 04/22/2026 at 01:55, 11 hours 41 minutes ago

Immutable Holdings Announces Director Resignation

View all ACCESSWIRE

Published on 04/22/2026 at 13:05, 31 minutes ago

EQS-Adhoc: ad pepper media International N.V.: Strongest first quarter in over 25 years of company history, EBITDA between EUR 6.5 and EUR 7.5 million expected for 2026
Published on 04/22/2026 at 13:00, 35 minutes ago

Infosys Announces Strategic Collaboration with OpenAI to Accelerate Enterprise AI Transformation and Unlock AI Value at Scale
Published on 04/22/2026 at 12:55, 40 minutes ago

innoscripta SE: Annual General Meeting approves dividend of EUR 4.00 per share and confirms Supervisory Board with strong capital markets expertise
Published on 04/22/2026 at 12:30, 1 hour 5 minutes ago

Schaeffler partners with Vietnamese humanoid robot manufacturer VinDynamics
Published on 04/22/2026 at 12:11, 1 hour 24 minutes ago

Humanoid robotics: Schaeffler enters into strategic partnership with Hexagon Robotics

View all EQS

Published on 04/22/2026 at 07:00, 6 hours 36 minutes ago

Q1 2026 sales. €229.5m at constant exchange rates. €215.5m at current exchanges rates
Published on 04/22/2026 at 06:55, 6 hours 41 minutes ago

Two Seasons In One Quarter
Published on 04/21/2026 at 19:15, 18 hours 21 minutes ago

AXA - Description of the Company’s share repurchase program
Published on 04/21/2026 at 18:00, 19 hours 36 minutes ago

Outstanding shares and voting rights statement at 31 March 2026
Published on 04/21/2026 at 17:49, 19 hours 46 minutes ago

Solocal - Q1 2026 Revenue and Activity

View all LES ECHOS COMFI WIRE

News